Please assess the completion status of the following clinical trial:

Trial Title: Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged 26-45;~* The subjects can understand and voluntarily sign the informed consent form ;~* Proven legal identity.~Exclusion Criteria:~* Travel history / residence history of communities with case reports within 14 days prior to the study;~* History of contact with a SARS-CoV-2 infection (positive in nucleic acid test) within 14 days prior to the study;~* Have contacted patients with fever or respiratory symptoms from communities with case reports within 14 days prior to the study;~* Two or more cases of fever and / or respiratory symptoms in a small contact area of volunteers, such as home, office etc. within 14 days prior to the study;~* History of SARS-CoV-2 infection or receiving COVID-19 vaccine;~* History of asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema;~* Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;~* Autoimmune disease (Systemic lupus erythematosus)or immunodeficiency / immunosuppression(HIV,history after organ transplantation)~* Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc.;~* Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;~* Thyroid disease or history of thyroidectomy, spleenlessness, functional spleenlessness, spleenlessness or splenectomy resulting from any condition;~* Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;~* Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;~* History of alcohol or drug abuse;~* Receipt of blood products within in the past 3 months；~* Receipt of other investigational drugs in the past 30 days；~* Receipt of attenuated live vaccines in the past 14 days;~* Receipt of inactivated or subunit vaccines in the past 7 days;~* Onset of various acute or chronic diseases within 7 days prior to the study;~* Axillary temperature \>37.0°C;~* Already pregnant (including a positive urine pregnancy test) or are breastfeeding, planning to get pregnant within 2 months;~* The subjects participated in other clinical trials during the follow-up period, or will be planned within 3 months;~* According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

- Gender: ALL
- Minimum Age: 26 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Inactivated SARS-CoV-2 vaccine Lot 1 (Type: EXPERIMENTAL): Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 1 according to 0,28-day immunization schedule.
- Inactivated SARS-CoV-2 vaccine Lot 2 (Type: EXPERIMENTAL): Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 2 according to 0,28-day immunization schedule.
- Inactivated SARS-CoV-2 vaccine Lot 3 (Type: EXPERIMENTAL): Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 3 according to 0,28-day immunization schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).